These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22417713)

  • 21. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism.
    Wells PS; Majeed H; Kassem S; Langlois N; Gin B; Clermont J; Taljaard M
    Thromb Res; 2010 Jun; 125(6):e259-64. PubMed ID: 20421126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Impact of Gene Polymorphisms on Anticoagulation Control With Warfarin.
    Jiang HH; Liu J; Wang YC; Ye HM; Li X; Zhou YX; Zhang W; Wang LS
    Clin Appl Thromb Hemost; 2018 May; 24(4):640-646. PubMed ID: 28401802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis.
    Zhang J; Chen Z; Chen C
    Meta Gene; 2016 Sep; 9():197-209. PubMed ID: 27617219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers.
    Mlynarsky L; Bejarano-Achache I; Muszkat M; Caraco Y
    Eur J Clin Pharmacol; 2012 May; 68(5):617-27. PubMed ID: 22071881
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions.
    Muszkat M; Blotnik S; Elami A; Krasilnikov I; Caraco Y
    Clin Ther; 2007 Mar; 29(3):427-37. PubMed ID: 17577464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.
    Borgiani P; Ciccacci C; Forte V; Sirianni E; Novelli L; Bramanti P; Novelli G
    Pharmacogenomics; 2009 Feb; 10(2):261-6. PubMed ID: 19207028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The Effect of
    Wang MY; Zhu T; Yu GJ; Huo Q; Yang YN
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Jan; 52(1):129-133. PubMed ID: 33474902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment.
    Cerezo-Manchado JJ; Roldan V; Rosafalco M; Anton AI; Arroyo AB; Garcia-Barbera N; Martínez AB; Padilla J; Corral J; Vicente V; Gonzalez-Conejero R
    Pharmacogenomics; 2014 May; 15(7):987-96. PubMed ID: 24956252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients.
    Singh O; Sandanaraj E; Subramanian K; Lee LH; Chowbay B
    Drug Metab Pharmacokinet; 2011; 26(2):130-6. PubMed ID: 21084764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients.
    Pautas E; Moreau C; Gouin-Thibault I; Golmard JL; Mahé I; Legendre C; Taillandier-Hériche E; Durand-Gasselin B; Houllier AM; Verrier P; Beaune P; Loriot MA; Siguret V
    Clin Pharmacol Ther; 2010 Jan; 87(1):57-64. PubMed ID: 19794411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deciphering Genetic Variants of Warfarin Metabolism in Children With Ventricular Assist Devices.
    Baban A; Iodice FG; Di Molfetta A; Cicenia M; Rizzo C; Agolini E; Drago F; Novelli A; Di Chiara L; Testa G; Amodeo A
    Pediatr Cardiol; 2021 Jun; 42(5):1082-1087. PubMed ID: 33837838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
    Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
    Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy.
    Pérez-Andreu V; Roldán V; Antón AI; García-Barberá N; Corral J; Vicente V; González-Conejero R
    Blood; 2009 May; 113(20):4977-9. PubMed ID: 19270263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of VKORC1, CYP2C9, and CYP4F2 Polymorphisms on Optimal Warfarin Dose: Does Ethnicity Matters?
    Li JX; Kim MH; Song K; Guo LZ; Jin EZ; Kim SJ; Lee KM; Serebruany V
    Am J Ther; 2021 Jul-Aug 01; 28(4):e461-e468. PubMed ID: 34228652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects.
    Kadian-Dodov DL; van der Zee SA; Scott SA; Peter I; Martis S; Doheny DO; Rothlauf EB; Lubitz SA; Desnick RJ; Halperin JL
    Vasc Med; 2013 Oct; 18(5):290-7. PubMed ID: 24029542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients.
    Zhong SL; Yu XY; Liu Y; Xu D; Mai LP; Tan HH; Lin QX; Yang M; Lin SG
    Pharmacogenet Genomics; 2012 Mar; 22(3):176-82. PubMed ID: 22198820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation between single nucleotide polymorphisms in CYP4F2 and warfarin dosing in Chinese valve replacement patients.
    Li JH; Ma GG; Zhu SQ; Yan H; Wu YB; Xu JJ
    J Cardiothorac Surg; 2012 Sep; 7():97. PubMed ID: 23013706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Influence of genetic polymorphisms and non-genetic factors on the maintenance dose of warfarin].
    Hou J; Dong X; Wang Y; Wang G; Dong L; Li-Ling J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Oct; 32(5):629-34. PubMed ID: 26418980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
    Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
    Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
    Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Konovalova NV; Postnov AIu; Kirienko AI
    Ter Arkh; 2011; 83(6):59-65. PubMed ID: 21786578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.